Targeting ATP Synthase by Bedaquiline as a Therapeutic Strategy to Sensitize Ovarian Cancer to Cisplatin
- 7 March 2023
- journal article
- research article
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75 (4) , 1271-1280
Abstract
Cisplatin is a common chemotherapeutic drug for treating ovarian cancer, but its clinical efficacy is hampered by intrinsic and acquired resistance. Previous studies had shown inhibiting oxidative phosphorylation overcomes cisplatin resistance in ovarian cancer. Studies reveal that bedaquiline, a clinically available antimicrobial drug, inhibits cancer via targeting mitochondria. This study systematically assessed the efficacy of bedaquiline in ovarian cancer and its underlying mechanism. Using a panel of ovarian cancer cell lines and normal ovary cells, we demonstrated bedaquiline is selective for anti-ovarian cancer activities. Furthermore, the sensitivity varied among different ovarian cancer cell lines regardless of their sensitivity to cisplatin. Bedaquiline inhibited growth, survival and migration, through decreasing levels of ATP synthase subunit, complex V activity, mitochondrial respiration and ATP. We further found that ovarian cancer displayed increased levels of ATP, oxygen consumption rate (OCR), complex V activity and ATP synthase subunits compared to normal counterpart. Combination index analysis showed that bedaquiline and cisplatin is synergistic. Bedaquiline remarkably enhanced the efficacy of cisplatin in inhibiting ovarian cancer growth in mice. Our study provides evidence to repurpose bedaquiline for ovarian cancer treatment and suggests that ATP synthase is a selective target to overcome cisplatin resistance in ovarian cancer.Keywords
Funding Information
- Hubei Provincial Natural Science Foundation of China (2021CFB582)
- Health Commission of Hubei Provincial scientific research project (WJ2021M069)
- Educational Commission of Hubei Province scientific research project (D20212103)
- the Science and Technology Development Project of Xiangyang (2021YL23)
This publication has 27 references indexed in Scilit:
- Structure of the mycobacterial ATP synthase F o rotor ring in complex with the anti-TB drug bedaquilineScience Advances, 2015
- Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencingBMC Cancer, 2015
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial functionNature, 2014
- Bedaquiline: a review of human pharmacokinetics and drug-drug interactionsJournal of Antimicrobial Chemotherapy, 2014
- The heterogeneity of ovarian cancerArchives of Gynecology and Obstetrics, 2013
- Mitochondria in Cancer Stem Cells: A Target for TherapyRecent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2013
- Power Cut: Inhibiting Mitochondrial Translation to Target LeukemiaCancer Cell, 2011
- The Diarylquinoline TMC207 for Multidrug-Resistant TuberculosisNew England Journal of Medicine, 2009
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Cells depleted of mitochondrial DNA (p0) yield insight into physiological mechanismsFEBS Letters, 1999